Literature DB >> 16075470

Cancer drugs offer hope, but at huge expense.

Alex Berenson.   

Abstract

Keywords:  Health Care and Public Health; Popular Approach/Source

Mesh：

Substances：

Year:  2005        PMID： 16075470

Source DB:  PubMed          Journal:  N Y Times Web        ISSN： 0362-4331


× No keyword cloud information.
  5 in total

1.  In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.

Authors:  Peter A Ubel; Scott R Berry; Eric Nadler; Chaim M Bell; Michael A Kozminski; Jennifer A Palmer; William K Evans; Elizabeth L Strevel; Peter J Neumann
Journal:  Health Aff (Millwood)       Date:  2012-04       Impact factor: 6.301

Review 2.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.

Authors:  Dan Greenberg; Craig Earle; Chi-Hui Fang; Adi Eldar-Lissai; Peter J Neumann
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506

3.  Impact of payment reform on chemotherapy at the end of life.

Authors:  Carrie H Colla; Nancy E Morden; Jonathan S Skinner; J Russell Hoverman; Ellen Meara
Journal:  J Oncol Pract       Date:  2012-05       Impact factor: 3.840

4.  Impact of payment reform on chemotherapy at the end of life.

Authors:  Carrie H Colla; Nancy E Morden; Jonathan S Skinner; J Russell Hoverman; Ellen Meara
Journal:  Am J Manag Care       Date:  2012-05-01       Impact factor: 2.229

5.  Reducing uncertainty in health-care resource allocation.

Authors:  T Simonsson; K Sjölund; P Bümming; H Ahlman; B Nilsson; A Odén
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.